ArticleBiomedicines2024
Insulin Resistance/Hyperinsulinemia as an Independent Risk Factor That Has Been Overlooked for Too Long.
Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Metabolomics profile in diabetes and blood glucose regulation: a systematic review.Frontiers in nutrition · 2026Pooled it
- Metabolic score for insulin resistance and the incidence of cardiovascular disease: a meta-analysis of cohort studies.Frontiers in endocrinology · 2025Pooled it
- Review
- Hallmarks of health: A Chinese medicine perspective.Innovation (Cambridge (Mass.)) · 2026Review
- The role of triglyceride-glucose (TyG) index in predicting mortality risk in critically ill patients with sepsis: a machine learning model in a cohort study.BMC medical informatics and decision making · 2026Article
- Insulin resistance: mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Insulin Resistance/Hyperinsulinemia Should Be Considered in the Prevention and Treatment of Essential Hypertension.Biomedicines · 2025Article
- The association of insulin resistance and obesity with uterine fibroids in non-diabetic populations: a cross-sectional study.Scientific reports · 2025Article
- Feature Reviews in Cardiovascular Diseases.Biomedicines · 2025Article
- Nanocarrier-enabled delivery of natural antiobesity agents.Nanomedicine (London, England) · 2025Review
- Dietary flavonoids may improve insulin resistance: NHANES, network pharmacological analyses and in vitro experiments.PloS one · 2025Article
- Network pharmacology-based insights into the role of gut microbiota metabolites in insulin resistance.Frontiers in microbiology · 2025Article
- Association between triglyceride-glucose and triglyceride glucose body mass index with risk of prediabetes: a multicenter Chinese medical examination cohort study.Frontiers in endocrinology · 2025Article
- Role of Peripheral and Central Insulin Resistance in Neuropsychiatric Disorders.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unfortunately, cardiovascular diseases and cancers are still the leading causes of death in developed and developing countries despite the considerable progress made in the prevention and treatment of diseases. Maybe we missed something? Insulin resistance (IR) with associated hyperinsulinemia (Hypein) is a silent pandemic whose prevalence is continually growing in developed and developing countries, now exceeding 51% of the general population. IR/Hypein, despite the vast scientific literature supporting its adverse action on the development of type 2 diabetes, cardiovascular alterations, tumors, neurological disorders, and cellular senescence, is not yet considered an independent risk factor and, therefore, is not screened in the general population and adequately treated. There are now numerous substances, drugs, and natural substances that, in association with the correction of a wrong lifestyle, can help to reduce IR/Hypein. We are convinced that the time has come to implement a prevention plan against this critical risk factor. Therefore, this manuscript aims to highlight IR/Hypein as an independent risk factor for type 2 diabetes, cardiovascular diseases, cancers, cellular senescence, and neuropsychiatric disorders, supporting our conviction with the available scientific literature on the topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.